Effectiveness of RSV Vaccines against RSV-Associated Thromboembolic Events.

ABSTRACT: We evaluated effectiveness of respiratory syncytial virus (RSV) vaccines against RSV-associated thromboembolic events among community-dwelling Medicare fee-for-service beneficiaries >65 years of age in the United States enrolled during October 1, 2023-March 30, 2024. RSV vaccines protected against RSV-associated thromboembolic events (effectiveness 79% [95% CI 74%-83%]) in the same season as vaccine receipt.

SUBMITTER: Wiegand RE 

PROVIDER: S-EPMC12928231 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature